Pfizer Inc Fourth-Quarter 2004 - Press Release
January 19, 2005 15:33

... Approximately 1% of the population suffers from schizophrenia. In the treatment of schizophrenia, clinical trials have demonstrated Geodon to be as effective as risperidone (Risperdal) and olanzapine (Zyprexa) in controlling both positive and negative symptoms, with a lower incidence of extra-pyramidal side effects than risperidone and significantly less weight gain and adverse changes in other metabolic indices than olanzapine. In a recent head-to-head study versus Zyprexa published in October 2004 in the American Journal of Psychiatry, Geodon demonstrated efficacy equivalent to Zyprexa in treating schizophrenia, while being associated with a lower incidence of weight gain and more favorable effects on lipid profile and other metabolic parameters. The Journal of Clinical Psychiatry published a head-to-head study comparing Geodon to risperidone in in-patients with schizophrenia or schizoaffective disorder. The study found that Geodon improved psychotic symptoms, was generally well tolerated, and demonstrated less effect on prolactin and weight than risperidone.